Ondine Biomedical Appoints Michael Behlke as CFO & COO to Drive Global Expansion

An announcement from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.

Ondine Biomedical Inc., a leader in light-activated antimicrobial treatments, has appointed Michael S. Behlke as CFO and COO to enhance its leadership team. Behlke’s extensive experience in financial and operational leadership, including notable achievements in scaling revenues and managing strategic partnerships, positions Ondine for accelerated growth and commercialization. This strategic appointment is expected to bolster Ondine’s efforts in expanding its infection prevention solutions globally, particularly in Canada, the UK/EU, and the U.S. post-FDA approval, thereby reinforcing its commitment to innovative antimicrobial solutions in healthcare.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, aimed at preventing and treating infections, including those caused by antibiotic-resistant bacteria. The company’s patented technology provides a safe and effective alternative to traditional antibiotics, addressing significant healthcare challenges.

YTD Price Performance: 28.57%

Average Trading Volume: 258,471

Technical Sentiment Consensus Rating: Sell

Current Market Cap: £45.45M

For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.